- Updated Therapeutic Implications - New alteration(s) with a tumor type-specific level of evidence

| Level | Gene  | Mutation            | Cancer Type          | Drug(s) Added to OncoKB™                                     | Evidence                                                                                                                                                                  |
| :---- | :---- | :------------------ | :------------------- | :----------------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| 4     | ERBB2 | Oncogenic Mutations | Biliary Tract Cancer | Neratinib, Trastuzumab Deruxtecan, Pertuzumab \+ Trastuzumab | PMID: [36746967](https://pubmed.ncbi.nlm.nih.gov/36746967/), [38710187](https://pubmed.ncbi.nlm.nih.gov/38710187/), [38748939](https://pubmed.ncbi.nlm.nih.gov/38748939/) |

####

- Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration

| Gene  | Mutation            | Cancer Type   | Level-associated Drug(s) in OncoKB™                                                                                                                  | Previous Level | Updated Level | Evidence                                                                                                        |
| :---- | :------------------ | :------------ | :--------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :-------------------------------------------------------------------------------------------------------------- |
| ERBB2 | Oncogenic Mutations | Breast Cancer | _Drug(s) added to OncoKB™:_<br/>Neratinib \+ Trastuzumab \+ Fulvestrant (Level 2\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Neratinib (Level 3A) | 3A             | 2             | Inclusion in Breast Cancer NCCN Guidelines V3.2025; PMID: [37597578](https://pubmed.ncbi.nlm.nih.gov/37597578/) |

- Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene | Mutation            | Cancer Type  | Level-Associated Drug(s) in OncoKB™ | Drug(s) Added to OncoKB™ | Evidence                                                                                                                                                                                                                                                         |
| :---- | :--- | :------------------ | :----------- | :---------------------------------- | :----------------------- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1     | NF1  | Oncogenic Mutations | Neurofibroma | Selumentinib (Level 1\)             | Mirdametinib (Level 1\)  | [FDA approval of mirdametinib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic); PMID: [39514826](https://pubmed.ncbi.nlm.nih.gov/39514826/) |

- Addition of 5 new genes:
  - DIS3L2
  - ERCC6
  - FANCB
  - MTHFR
  - NFATC2
